Literature DB >> 24816798

The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis.

Tao Zhang1, Dong-Ming Zhang, Da Zhao, Xiao-Ming Hou, Xiao-Jun Liu, Xiao-Ling Ling, Shou-Cheng Ma.   

Abstract

To investigate the association of Osteopontin (OPN) expression in tumor tissue with clinicopathological features of non-small cell lung carcinoma (NSCLC) patients. Publications assessing the clinicopathological characteristics and prognostic significance of OPN in expression NSCLC were identified up to March 2014. A meta-analysis of eligible studies was performed using standard statistical methods to clarify the association between OPN expression and these clinical parameters. A total of eleven studies met the inclusion criteria, and included 1536 cases of NSCLC tumor tissue and 340 cases of normal lung tissue. The OPN expression rate in NSCLC tissue was higher than normal tissue [Odds ratio (OR) 6.427; 95% confidence interval (CI) 4.689-8.808; P = 0.000]. Simultaneously, we also found that OPN expression was positively associated with stage (OR 0.332; 95% CI 0.250-0.440; P = 0.000), lymph node metastasis (OR 3.094; 95% CI 2.295-4.172; P = 0.000), tumor size (tumor size <3 cm vs. ≥3 cm; OR 0.484; 95% CI 0.303-0.773; P = 0.002) and pathology (OR 0.611; 95% CI 0.466-0.800; P = 0.000). It was unrelated that OPN expression in NSCLC tissue with and degree of differentiation and other clinical features (P > 0.05). Experimental findings indicate that, OPN plays a crucial role in the development of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816798     DOI: 10.1007/s10735-014-9574-3

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  43 in total

1.  [Correlation between OPN and P21 in non-small cell lung cancer].

Authors:  Xuelin Zhang; Song Xue; Jiahao Zheng; Sha Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2007-08-20

2.  [Expression and clinicopathologic significance of OPN, CD44v6 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lung].

Authors:  Jun Yu; Tiecheng Pan; Jun Li; Xiang Wei; Tao Chen; Min Hu; Dingwei Song; Ligang Liu; Peng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2006

3.  A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Authors:  C Ostheimer; M Bache; A Güttler; M Kotzsch; D Vordermark
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

4.  Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.

Authors:  Bing-Sheng Sun; Yue Li; Zhen-Fa Zhang; Jian You; Chang-Li Wang
Journal:  Ann Thorac Surg       Date:  2013-10-03       Impact factor: 4.330

Review 5.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

6.  Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer.

Authors:  Yong Liang; Hui Li; Bin Hu; Xing Chen; Jin-Bai Miao; Tong Li; Bin You; Qi-Rui Chen; Yi-Li Fu; Yang Wang; Sheng-Cai Hou
Journal:  Chin J Cancer Res       Date:  2011-03       Impact factor: 5.087

7.  EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma.

Authors:  K Matušan-Ilijaš; G Damante; D Fabbro; G Dorđević; I Hadžisejdić; M Grahovac; M Avirović; B Grahovac; N Jonjić; K Lučin
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

8.  Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression.

Authors:  Yanhua Wu; Wenjun Jiang; Yingming Wang; Jun Wu; Hexige Saiyin; Xiaojing Qiao; Xinyu Mei; Bin Guo; Xiao Fang; Lu Zhang; Huiling Lou; Chaoqun Wu; Shouyi Qiao
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

9.  Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer.

Authors:  Ane Kongsgaard Rud; Marius Lund-Iversen; Gisle Berge; Odd Terje Brustugun; Steinar K Solberg; Gunhild M Mælandsmo; Kjetil Boye
Journal:  BMC Cancer       Date:  2012-08-01       Impact factor: 4.430

10.  Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer.

Authors:  Seon-Sook Han; Seung-Joon Lee; Woo Jin Kim; Dong Ryeol Ryu; Jun Yeon Won; Shinyoung Park; Myeong Ju Cheon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-09-30
View more
  15 in total

1.  Transformer 2β (Tra2β/SFRS10) positively regulates the progression of NSCLC via promoting cell proliferation.

Authors:  Lili Ji; Tingting Ni; Yanbo Shen; Qun Xue; Yifei Liu; Buyou Chen; Xuefan Cui; Liting Lv; Xiafei Yu; Yuan Cui; Xiaoning Lu; Jie Chen; Guoxin Mao; Yuchan Wang
Journal:  J Mol Histol       Date:  2014-06-21       Impact factor: 2.611

Review 2.  Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis.

Authors:  Bin Peng; Yi-Han Wang; Zhuo Huang; Shi-Jian Feng; Yong-Sheng Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer.

Authors:  Yongqiang Li; Zhi Wang; Yijiang Li; Ruijun Jing
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

4.  Upregulated expression of ILF2 in non-small cell lung cancer is associated with tumor cell proliferation and poor prognosis.

Authors:  Tingting Ni; Guoxin Mao; Qun Xue; Yifei Liu; Buyou Chen; Xuefan Cui; Liting Lv; Liangliang Jia; Yuchan Wang; Lili Ji
Journal:  J Mol Histol       Date:  2015-06-10       Impact factor: 2.611

5.  RNA-seq analysis of lung adenocarcinomas reveals different gene expression profiles between smoking and nonsmoking patients.

Authors:  Yafang Li; Xiangjun Xiao; Xuemei Ji; Bin Liu; Christopher I Amos
Journal:  Tumour Biol       Date:  2015-06-17

6.  Selective expression of transthyretin in subtypes of lung cancer.

Authors:  Shuai Hao; Suozhu Sun; Xueyuan Xiao; Dacheng He; Liyun Liu
Journal:  J Mol Histol       Date:  2016-03-04       Impact factor: 2.611

7.  The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.

Authors:  Jing Wang; Hong Wei; Baoxia Zhao; Mei Li; Weipeng Lv; Ling Lv; Bo Song; Shen Lv
Journal:  J Mol Histol       Date:  2014-07-10       Impact factor: 2.611

8.  Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis.

Authors:  Yang Liu; Xiaobin Gu; Qunying Lin; Tian Tian; Lijuan Shao; Chao Yuan; Bo Zhang; Kexing Fan
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  miR-335 inhibited cell proliferation of lung cancer cells by target Tra2β.

Authors:  Jian Liu; Tingting Bian; Jia Feng; Li Qian; Jianguo Zhang; Daishan Jiang; Qing Zhang; Xiaoli Li; Yifei Liu; Jiahai Shi
Journal:  Cancer Sci       Date:  2017-12-15       Impact factor: 6.716

10.  Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis.

Authors:  Dan Li; Wang Qian; Ruo Ran Li; Jinghao Zhang; K E Li; Yanmin Wu
Journal:  Biomed Rep       Date:  2016-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.